Nicotine addiction begins with high-affinity binding of nicotine to acetylcholine (ACh) receptors in the brain. The end result is over 4,000,000 smoking-related deaths annually worldwide and the largest source of preventable mortality in developed countries. Stress reduction, pleasure, improved cognition and other central nervous system effects are strongly associated with smoking. However, if nicotine activated ACh receptors found in muscle as potently as it does brain ACh receptors, smoking would cause intolerable and perhaps fatal muscle contractions. Despite extensive pharmacological, functional and structural studies of ACh receptors, the basis for the differential action of nicotine on brain compared with muscle ACh receptors has not been determined. Here we show that at the a4b2 brain receptors thought to underlie nicotine addiction, the high affinity for nicotine is the result of a strong cation-p interaction to a specific aromatic amino acid of the receptor, TrpB. In contrast, the low affinity for nicotine at the muscletype ACh receptor is largely due to the fact that this key interaction is absent, even though the immediate binding site residues, including the key amino acid TrpB, are identical in the brain and muscle receptors. At the same time a hydrogen bond from nicotine to the backbone carbonyl of TrpB is enhanced in the neuronal receptor relative to the muscle type. A point mutation near TrpB that differentiates a4b2 and muscle-type receptors seems to influence the shape of the binding site, allowing nicotine to interact more strongly with TrpB in the neuronal receptor. ACh receptors are established therapeutic targets for Alzheimer's disease, schizophrenia, Parkinson's disease, smoking cessation, pain, attention-deficit hyperactivity disorder, epilepsy, autism and depression 1 . Along with solving a chemical mystery in nicotine addiction, our results provide guidance for efforts to develop drugs that target specific types of nicotinic receptors.
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Nicotinic acetylcholine receptors (nAChRs) comprise a family of $20 homologous subtypes that mediate fast synaptic transmission throughout the central and peripheral nervous systems 2 . The neuronal receptors are found in the central nervous system (CNS) and autonomic ganglia. Of these, the subtype most strongly associated with nicotine addiction and the target of recently developed smoking cessation drugs is termed a4b2 (refs 3-7). The high nicotine affinity of a4b2 receptors, when combined with the ability of nicotine to cross the blood-brain barrier and its favourable pharmacokinetics, allows nicotine at the submicromolar concentrations in tobacco smoke to activate acutely these receptors, providing reward, cognitive sensitization and perhaps other effects. In addition, the highaffinity interaction allows smoked nicotine to act as an intracellular pharmacological chaperone of a4b2 receptors, leading to the upregulation of receptors thought to underlie effects of chronic exposure 6, 8 . In previous studies of the nAChR of the neuromuscular junction (muscle type), we showed that an important contributor to ACh binding is a cation-p interaction to a specific tryptophan (called TrpB, residue 149, Fig. 1 ) 9 . These results were subsequently supported by the important series of crystal structures of ACh binding proteins (AChBP) 10, 11 . These structures revealed the 'aromatic box' structural motif of Fig. 1 , and the aligning residues are predominantly aromatic throughout the Cys-loop family of neurotransmitter-gated ion channels. In other Cys-loop receptors, a cation-p interaction between the natural agonist and one of the aromatics is always seen, although its precise location varies 12 . Interestingly, when nicotine activates the muscle-type nAChR, there is no cation-p interaction 13 , consistent with its relatively low affinity for this receptor. This suggested that a cation-p interaction could discriminate between highaffinity neuronal receptors and low-affinity muscle-type receptors. However, subtle effects must be involved, as the nAChRs of the CNS and neuromuscular junction are homologous throughout most regions of sequence and are essentially identical in the immediate vicinity of the agonist binding site (Supplementary Fig. 1 ). Here we describe studies of the a4b2 neuronal receptor. We find a remarkable alteration of binding behaviour: both ACh and nicotine make a strong cation-p interaction to TrpB. In addition, a hydrogen bond from nicotine to the backbone carbonyl of TrpB that is weak in the muscle-type is much stronger in the a4b2 receptor. Taken together, these two noncovalent interactions fully rationalize the differential affinity of nicotine in the brain versus the neuromuscular junction.
A cation-p interaction between a drug and a receptor can be revealed by incorporation of a series of fluorinated amino acid analogues (Fig. 2) ; a consistent trend in receptor response indicates a binding interaction. Such an experiment is enabled by the nonsense suppression methodology for incorporation of unnatural amino acids into receptors and channels expressed in Xenopus oocytes. Although we have found the nonsense suppression methodology to be broadly applicable 14, 15 , implementing the methodology for study of the a4b2 neuronal nAChRs proved to be especially challenging, requiring new strategies. The a4b2 receptors are expressed in Xenopus oocytes at inadequately low levels for nonsense suppression experiments. However, recent studies showed that the Leu99Ala (L99A) mutation in the M2 transmembrane helix of the a4 subunit greatly improves expression without altering the pharmacological selectivity of the receptor 16 . (In Cys-loop receptors, the highly homologous M2 sequences are often compared by numbering from the cytoplasmic end, termed position 19.) Therefore, all studies of a4b2 described here included this mutation. As with other mutations of L99, the L99A mutation lowers the agonist concentration for halfmaximum response (EC 50 ) by influencing receptor gating in ways that are fairly well understood and that do not distort the present analysis of the binding site (some 60 Å from the 99 position) 17, 18 . In addition, previous studies of the muscle-type receptor used a comparable mutation at L99, and control experiments established that it did not alter binding trends 9, 19 . The nAChRs are pentameric. The muscle-type receptor has a precise stoichiometry of (a1) 2 b1cd. However, the a4b2 receptor can have variable stoichiometry. In particular, there are two forms of a4b2, (a4) 2 (b2) 3 and (a4) 3 (b2) 2 , which we refer to hereafter as A2B3 and A3B2, respectively 8, 20, 21 . Agonist binding sites are at the appropriate a-b interfaces. The A2B3 form has higher sensitivity for nicotine and may be upregulated during chronic exposure to nicotine; our studies have focused on it. Controlling the ratios of messenger RNAs injected into the oocyte can reliably control subunit stoichiometry in the wild-type receptor. However, in a nonsense suppression experiment, the subunit that contains the stop codon where the unnatural amino acid has been incorporated can show low and variable expression levels. Therefore we sought a second, independent indicator of the stoichiometry of the a4b2 receptor. We now report that the A2B3 and A3B2 forms of the a4(L99A)b2 receptor show markedly different rectification behaviours. As indicated by either voltage ramp or voltage jump experiments, A2B3 is substantially more inward rectifying than A3B2 (Supplementary Fig. 2) . Thus, in all our experiments with unnatural amino acids, the stoichiometries of mutant receptors are monitored by measuring current-voltage relations with voltage jumps. For each mutant receptor studied, we determined the fraction (outward current at 170 mV/ inward current at -110 mV), and a value #0.1 establishes the desired A2B3 stoichiometry (Supplementary Table 1 and Supplementary Discussion). With these methodological developments in hand, incorporation of unnatural amino acids into the a4b2 receptor becomes feasible (Fig. 3) .
As shown in Supplementary Table 1 and Fig. 4 , a compelling 'fluorination' trend is seen for both ACh and nicotine at TrpB of the a4b2 receptor. This is in contrast to the results at the muscletype receptor, in which no such trend is seen for nicotine activation. Further support for an important cation-p interaction for both agonists is provided by the large perturbation induced by a cyano (CN) group-which is strongly deactivating in a cation-p interaction-compared to a bromo (Br) group, which is roughly isosteric to a cyano group but much less deactivating.
We have also evaluated other residues that constitute the aromatic box of the ACh binding site (Supplementary Table 1 ). The results for a4b2 very much parallel our previous findings for the muscle-type receptor (Supplementary Discussion). This indicates that it is specifically the interaction with TrpB that discriminates the two receptor subtypes.
The EC 50 values reported here represent a measure of receptor function; shifts in EC 50 can result from changes in ligand binding and/or receptor gating properties. By ascribing the results to attenuation of a cation-p interaction, we are effectively concluding that it is ligand binding that is being modulated by fluorination, but that conclusion is not incontrovertible. To resolve this ambiguity, we evaluated the gating behaviours of key receptors using single-channel recording. For the wild type and the receptor with 5,6,7-trifluorotryptophan (F 3 -Trp) at TrpB, we compared the probabilities that the channel is open (P open ) at nicotine concentrations that evoke halfmaximal macroscopic steady-state currents (EC 50 5 0.08 mM and 1.2 mM, respectively). Any differences between the two P open values must result from differences in gating behaviours. As suggested by Fig. 5 and as confirmed by further single-channel analysis ( Supplementary  Fig. 3 and Supplementary Discussion), the wild-type and mutant receptors have P open values that are essentially indistinguishable. Thus, the shift in EC 50 for F 3 -Trp is primarily, if not exclusively, a consequence of changes in binding. Fluorination of TrpB of the a4b2 (A2B3) receptor primarily has an impact on the sensitivity to nicotine by decreasing nicotine's cation-p interaction with this residue.
These results indicate that nicotine is positioned more closely to TrpB in the a4b2 agonist binding site than in the muscle type. This suggested that another nicotine-binding interaction could also be altered. An important chemical distinction between ACh and nicotine is that only the latter can act as a hydrogen bond donor, through the pyrrolidine N 1 -H (Fig. 2a) . Examination of the AChBP crystal structures (Fig. 1) 22 suggested that the backbone carbonyl associated with TrpB could act as the hydrogen bond acceptor, and several groups have shown the importance of this interaction [22] [23] [24] . Previously, we probed this potential hydrogen bond in the muscletype receptor by replacing the (i 1 1) residue with its a-hydroxy analogue (Fig. 2c) . This converts the backbone amide to a backbone ester, which is well established to be a substantially poorer hydrogen bond acceptor. In the muscle-type receptor, this change raised the . We now find that for precisely the same change in the a4b2 receptor, the nicotine EC 50 increases 19-fold, a relatively large effect for such a subtle mutation [26] [27] [28] . Recall that the backbone ester substitution does not destroy the hydrogen bond, it simply attenuates it. Notably, ACh, which cannot make a conventional hydrogen bond to the carbonyl, shows no shift in EC 50 in response to this mutation (Supplementary Table 1 ).
This establishes that the ester mutation does not globally alter the binding/gating characteristics of the receptor.
The differential affinity of nicotine for a4b2 versus muscle-type receptors results from stronger interactions in the former with TrpB-both cation-p and hydrogen bonding. Because the two receptors are identical with regard to the five residues that make up the aromatic box, a factor 'outside the box' must be influencing its precise geometry, such that nicotine can approach TrpB more closely in a4b2 than in muscle-type nAChR. Pioneering work has identified residues responsible for the fact that a4b2 receptors show consistently higher affinity than the homopentameric a7 neuronal receptors 29 . At a particular residue in loop B-position 153, just four residues from TrpB-mutations strongly influence affinity. In high-affinity a4b2 receptors this residue is a Lys, and this residue is proposed to help shape the aromatic box by forming a backbone hydrogen bond between loops B and C (Fig. 1) . In the lower affinity a7 neuronal receptor, residue 153 is a Gly, and molecular dynamics simulations of a7 suggest that a Gly at 153 discourages the formation of the hydrogen bond between loops B and C. Interestingly, the aligned residue in the muscle-type receptor is also Gly, and a naturally occurring G153S mutation is gain-of-function and associated with a congenital myasthenic syndrome 30 . We now report that the muscle-type a1 G153K mutant shows much higher affinity for nicotine, and that, when this mutation is present, the cation-p interaction to TrpB is strong. The data are summarized in Supplementary Table 1 and Fig. 4 . As expected, the ACh cation-p interaction is maintained in the muscle-type receptor with the G153K mutation. These data indicate that the loop B-loop C hydrogen bond that is naturally present in a4b2 shapes the aromatic box so that nicotine can make a closer contact to TrpB, and that this structural feature is absent or weaker in the muscle-type receptor.
Taken together, the present results indicate that the higher affinity of nicotine in the brain relative to the neuromuscular junction is a consequence of enhanced interactions with TrpB. A cation-p interaction that is absent in the muscle-type receptor is quite strong in a4b2. In addition, a hydrogen bond to a backbone carbonyl that is weak in the muscle type is enhanced in a4b2. Both effects are quite substantial, and in combination they are more than adequate to account fully for the differential sensitivity to nicotine of the two receptors. The side chain of residue 153 in loop B distinguishes the two receptor types and apparently influences the shape of the binding site aromatic box, allowing a stronger interaction between nicotine and TrpB in high-affinity receptors.
METHODS SUMMARY
Whole-cell electrophysiological characterization of agonist-induced responses. Rat a4b2 and mouse (a1) 2 b1cd ion channels were expressed in Xenopus laevis oocytes. For a4b2 receptors, subunit stoichiometry was controlled by varying the a4:b2 subunit ratio and verified by voltage-jump experiments. Dose-response measurements for these channels were performed with a holding potential of 260 mV. Unnatural amino acid/a-hydroxy acid incorporation. Unnatural amino acids and a-hydroxy acids were prepared, coupled to dCA and ligated to 74-mer THG73 as described previously 15 . Single-channel characterization of a4b2. Single-channel recording was performed in the cell-attached configuration with a pipette potential of 1100 mV as described previously 27 . P open values were calculated from eventdetected data using Clampfit 9.2 single-channel search.
See associated Nature Protocols paper by X.X. et al. (in the press).
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